GLP-1 RAs recently appearing on the market, in particular liraglutide, semaglutide and tirzepatide (a GIP/GLP-1 RA dual agonist) seek to overcome the problem of the short plasma half-life of native GLP-1 through (i) changing the amino acid sequence of the peptide so that it is no longer broken down by DPP-4, and/or (ii) attaching a long acyl chain to the peptide, thus allowing it to bind to albumin, and avoid rapid elimination via the kidney
GLP invented the now famous JDC-1 hybrid tilt strobe over seven years ago, and recently released this reimagined model, the JDC Burst 1, which is now IP rated, super-fast and has RGBW plates rather than the original RGB, allowing for much better colour mixing, and, if required, a full white face to match the centre white strobe tube
So its also like kind of interesting, you know, Im I very often will have somebody on, you know, a half of a statin or, you know, like, I mean, you know, will adjust things, you know, based on their digestion or based on, you know, things that we call out
These medications are important in preventing life-threatening complications like delirium tremens (DTs), especially in severe cases